DOCSLIB.ORG

Drug Discovery and Preclinical Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Discovery and Preclinical Development Drug Discovery and Preclinical Development Neal G . Simon , Ph . D. Professor Department of Biological Sciences Disclaimer “Those wh o h ave k nowl ed ge, d on’t predi ct . Those who predict, don’t have knowledge.” Lao Tzu, 6th Century BC Chinese Poet Discovery and Preclinical Development I. Background II. The R&D Landscape III. ItidTftiInnovation and Transformation IV. The Preclinical Development Process V. Case Study: Stress-related Affective Disorders Serendipity or Good Science: Building Opportunity Hoffman Osterhof I. Background Drug Development Process Biopharmaceutical Drug Development: Attrition Drug FDA Large Scale Discovery Pre-Clinical Clinical Trials Review Manufacturing / Phase IV Phase I Phase III 20-100 1000-5000 Volunteers Volunteers 10,000 bmitted 1 FDA Com- bmitted 250 Compounds 5 Compounds uu pound uu AdApproved s Drug NDA S NDA IND S Phase II 100-500 Volunteers 5 years 1.5 years 6 years 2 years 2 years Quelle: Burrell Report Biotechnology Industry 2006 Capitalized Cost Estimates per New Molecule *All R&D costs (basic research and preclinical development) prior to initiation of clinical testing ** Based on a 5-year shift and prior growth rates for the preclinical and clinical periods. DiMasi and Grabowski (2007) II. The Research & Developppment Landscape R&D Expenditures and Return on Investment: A Declining Function Phrma (2005); Tufts CSDD (2005) R&D Expenditures 1992-2004 and FDA Approvals Hu et al (2007) NIH Budget by Area Pharmaceutical Industry: Diminishing Returns “That is why the business model is under threat: the ability to devise new molecules through R&D and bring them to market is not keeping up with what ’s being lost to generic manufacturers on the other end. This situation requires new thinking, new urgency, new capabilities.” FdHFred Hassan, CEOShiCEO Schering-Plough , 2005 Saltzmann (2006) III. Innovation and Transformation Innovation Models and Transformation Hu et al (2007) Innovation Models: In-licensing and Acquisitions Saltzmann (2006) Me Too Drugs: Antidepressants 1986 Fluvoxamine (Luvox; Solvay) SSRI 1987 Fluoxetine (Prozac; Lilly) SSRI 1992 Sertraline* (Zoloft; Pfizer) SSRI/NRI 1993 Venlafaxine (Effexor; Wyeth) SSRI/NRI 1996 Buproprion (Wellbutrin; Wyeth) SNRI/DRI 2002 Escitalopram (Lexapro; Forrest) SSRI 2004 Duloxetine (Cymbalta; Lilly) SSRI/NRI Personalized Medicine (sort of) Discovery & Preclinical Development IV. Discovery and Preclinical Development Discovery and Preclinical Development Lead Selection and Drug Candidate Preclinical Drug Optimization (iterative) Confirmation Characterization Regul a Efficacy Assessment: Does it work? tory Sub ADME Profiling: How can it be delivered and what does the body do? m ission t Toxicology/Safety Pharmacology Assessment: Is it safe? o FDA Pharmaceutics: Is the manufacture viable and controllable? Adapted from TetraQ Stage 1: Lead Selection and Optimization Essential Pharmaceutics • Structural Characterization • Impurity Identification • Solubility assessment • Prototype formulation • Stability testing Screening Efficacy Early Toxicology Early ADME • In silico profiling • Off targe t screen • In vitro models • Develop simple • In vitro cytotoxicity • In vivo models analytical method • Preliminary AMES • Other • Measure membrane • hERG binding permeability • Plasma Stability Adapted from TetraQ Stage 2: Drug Candidate Confirmation Data from Lead Optimization Stage Preliminary CMC “Benchmark” in Preliminary (Chemistry, ADME Profiling Manufacture and vivo Models Toxicology Control) • Optimized • Formulation for analytical • Maximum GLP Toxicology method tolerated dose • Sta bility t esti ng • IiIn vivo modldels development (MTD) of active • Validated • Basic pharma- • Repeat Dose ingredient models cokinetics (PK) (non-GLP) • Detailed • Models in other &Oral& Oral • Preliminary phihysicoch emi ilcal disease areas Bioavailability Cardiovascular characterization • Determine Safety • Impurity metabolism of Pharmacology analysis drug Adapted from TetraQ Stage 3: Preclinical Drug Characteristics Data from Prior Stages Detailed Preclinical Comprehensive GLP Toxicology CMC ADME Package • analytical method • acute study • ICH Stability development • subchronic repeat Testing • Comprehensive dose study • ICH impur ity Pharmacokinetics • Genotoxicity analysis • GLP TK Battery •Develop prototype • Comprehensive • Safety clinical formulation identification of Pharmacology metabolites Regulatory Submission or Presentation to Pharma Adapted from TetraQ V. Case Study: Stress-related Affective Disorders Overview GPCR‐targeted oral small molllecule drugs for stress, mood, and behavior disorders First compounds: vasopressin receptor antagonists Somewhere between skunk works, serendippyity, and good planning AVP: Biological Diversity Invertebrate & Vertebrate Vertebrate Behavior Physiology fluid regulation communication carbhdbohydrat e met tbliabolism sexualbl beh avi or thermoregulation pair bonding reproductive function paternal/maternal care social memory stress-related disorders imppyulsivity/violence Hypothalamic-Pituitary Adrenal Axis Compound #1 Profile: • Novel oral vasopressin AVP receptor antagonist • Initial clinical development for stress‐related affective illness • Serenic activity established in rodent models Market: • $20+ billion World Wide Market • 35 million people affected by anxiety and depression in US alone Status: • Phase I completed • Phase II in planning Compound #1: Preclinical Development I. in vitro Biology and PK II. IND-directed Toxicology and Pharmacolo gy III. Behavior and Neuroimaging * NIMH (MH063663), NIH Roadmap Initiative, NCI Binding and Function at Human AVP Receptor A competitive binding assay was conducted in CHO cells transfected with human AVP receptor (left panel). Compound #1 inhibited AVP - mediated phosphatidyl inositol turnover with a Ki value at 0.16 nM (right panel). In hibition of H uman AVP Bi ndi ng b y Inhibition of AVP Induced IP3 Production 1000 3500 VP AA 800 3000 EC50 = 0 .87 nM 3 H- 3 Ki = 0.16 nM 2500 600 H-IP IC50 = 0.49 nM 3 2000 Ki = 0.30 nM 400 M of 1500 of Bound PP C 1000 200 CPM 500 0 0 -13 -12 -11 -10 -9 -8 -7 -6 -5 -13 -12 -11 -10 -9 -8 -7 -6 -5 Concentration: Log M Concentration: Log M Compound #1: Selectivity Tested at vs 64 receptors including 35 GPCRs Receptor Class #1 (% inhibition) Vasopressin 1 80.40% NtNeurotransm ittltditter related -20% to +20% Steroids -20% to +20% Ion channels -20% to +20% Second messengers -20% to +20% Prostaglandins -20% to +20% Gthft/hGrowth factors/hormones -20% to +20% Brain/gut peptides -20% to +20% (not including Vasopressin 1) Enzymes -20% to +20% *-20% to +20% is considered “baseline,” which is defined as “inactive” Compound #1: IND-Directed Studies Genetic Safety Mammalian Toxicology Pharmacology Toxicology AMES hERG 7-day Repeat Oral (gavage) in Rats Chromosomal Rat Irwin Aberration 28-day Repeat Oral Cardiovascular & (gavage) dose in Rats Pulmonary Safety in Dogs 7-day DRF in Dogs 28-day Repeat Oral (capsule) dose in Dogs (just completed) Compound #1: hERG Test for QT Prolongation Values shown are Inhibition of Current (%) + SEM Test Compound % Inhibition SEM Compound 1 32.9 1.5 Positive Control 76.7 2.8 (tfterfena dine 60 nM) Conducted by ChanTest, Inc; Covance GLP study 7252-117 Results: IC50 = 1.9 μM indicating low risk of cardiac arrhythmias based on anticipated clinical dosing Compound #1 Blocks Vasopressin-induced Increases in Blood Pressure Blood Pressure 25 Blood Pressure 20 Hg) Hg) mmmm 15 ** sure (msure (m 10ssss 5 ** lood prelood pre 0BB AVPvehicle Only 0.16 0.4 1 2.5 Dose (mg/kg) ** p<0.05 vs vehicle Vasopressin is Linked to Stress-related Disorders R. Landgraf (2006). Involvement of the vasopressin system in stress-related disorders. CNS & Neurological Disorders – Drug Targets 5, 167-179 Increased synthesis, content, and release of AVP in PVN in HAB and LAB rats under basal conditions Elevated Vasopressin is Linked to Stress-related Disorders: Rodent Model AVP in the paraventricular nucleus (PVN) flanking the 3rd ventricle (3V) in HAB (high anxiety) and LAB (low anxiety) mice. Elevated Plus Maze Forced Swim Test Bunck et al. (2009) AVP mRNA in Supraoptic and Paraventricular Nuclei from Depressed and Control Individuals AVP mRNA in PVN and SON in depressed (n=9) and Signal on film in SON and PVN control patients (n=8) Meynen et al (2006) fMRI: Imaging Stress/Arousal in Awake Animals Piloerection is an index of autonomic activation Compound #1 Blocks Stress & Arousal: Composite View Mate/Intruder + Compound #1 Imaging on awake rats Treatment Mate & Intruder Major Brain Stress/Arousal in #1: Blockadeof Compound Amygdala Cortex Hippocampus Thalamus Regions Activation of Olfactory and Reward Pathways in the Presence of Compound #1 but not Fluoxetine Serendipity or Good Science: Building Opportunity Hoffman Osterhof Thanks for Your Time and Attention.
Load more

Recommended publications
  • Preclinical Toxicology – Points to Consider in Program Design
    To view this booklet online, please visit PacificBioLabs.com. Preclinical Toxicology – Points To Consider in Program Design PACIFIC BIOLABS – YOUR PARTNER FOR PRECLINICAL SAFETY TESTING As The Service Leader in Bioscience Testing, Pacific BioLabs (PBL) strives to help our clients deliver safe and effective pharmaceuticals to the patients who need them. Well designed and executed preclinical studies are critical to the success of any drug development program. They must reliably assess the safety of a new drug entity, laying the groundwork for clinical trials and ultimately, regulatory approval. Pacific BioLabs interacts closely with our clients, providing quality nonclinical testing results to meet regulatory requirements and guide your drug development decisions. As part of our commitment to clients, we have prepared a pair of publications that will assist you in planning your preclinical testing program. This publication, Preclinical Toxicology – Points to Consider in Program Design, gives an overview of the drug development process, describes the contents of a typical Common Technical Document, shows the relative timing of various studies required for a successful IND and NDA, and presents advice on selecting and working with contract toxicology labs and other CROs. PBL’s companion publication, Preclinical Toxicology – Guidance for Industry – ICH Guidances, is available on our website at PacificBioLabs.com. It presents two major ICH guidance documents that directly address safety testing of new pharmaceuticals: Guidance M3 – Nonclincal Safety Studies for the Conduct of Human Clinical Trials for Pharmaceutical and Guidance S6 – Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. The FDA website http://www.fda.gov/cder/guidance contains these two documents along with a variety of other references on regulatory expectations for the nonclinical development of NCEs.
    [Show full text]
  • Research and Development in the Pharmaceutical Industry
    Research and Development in the Pharmaceutical Industry APRIL | 2021 At a Glance This report examines research and development (R&D) by the pharmaceutical industry. Spending on R&D and Its Results. Spending on R&D and the introduction of new drugs have both increased in the past two decades. • In 2019, the pharmaceutical industry spent $83 billion dollars on R&D. Adjusted for inflation, that amount is about 10 times what the industry spent per year in the 1980s. • Between 2010 and 2019, the number of new drugs approved for sale increased by 60 percent compared with the previous decade, with a peak of 59 new drugs approved in 2018. Factors Influencing R&D Spending. The amount of money that drug companies devote to R&D is determined by the amount of revenue they expect to earn from a new drug, the expected cost of developing that drug, and policies that influence the supply of and demand for drugs. • The expected lifetime global revenues of a new drug depends on the prices that companies expect to charge for the drug in different markets around the world, the volume of sales they anticipate at those prices, and the likelihood the drug-development effort will succeed. • The expected cost to develop a new drug—including capital costs and expenditures on drugs that fail to reach the market—has been estimated to range from less than $1 billion to more than $2 billion. • The federal government influences the amount of private spending on R&D through programs (such as Medicare) that increase the demand for prescription drugs, through policies (such as spending for basic research and regulations on what must be demonstrated in clinical trials) that affect the supply of new drugs, and through policies (such as recommendations for vaccines) that affect both supply and demand.
    [Show full text]
  • (1) Jan–Mar 2018
    HIPPOCRATIC JOURNAL OF UNANI MEDICINE Volume 13, Number 1, January – March 2018 Hippocratic J. Unani Med. 13(1): 1 - 74, 2018 CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) Government of India Hippocratic Journal of Unani Medicine Editorial Board Editor-in-Chief Prof. Asim Ali Khan Director General, CCRUM Editor Mohammad Niyaz Ahmad Research Officer (Publication), CCRUM Associate Editors Dr. Naheed Parveen Assistant Director (Unani), CCRUM Dr. Ghazala Javed Research Officer (Unani) Scientist – IV, CCRUM Dr. T. Mathiyazhagan Senior Consultant (Scientific Writing), CCRUM Advisory Board - International Dr. Fabrizio Speziale, Paris, FRANCE Dr. Suraiya H. Hussein, Kuala Lumpur, MALAYSIA Mrs. Sadia Rashid, Karachi, PAKISTAN Prof. Ikhlas A. Khan, USA Dr. Maarten Bode, Amsterdam, THE NETHERLANDS Prof. Abdul Hannan, Karachi, PAKISTAN Prof. Usmanghani Khan, Karachi, PAKISTAN Prof. Rashid Bhikha, Industria, SOUTH AFRICA Advisory Board - National Prof. Allauddin Ahmad, Patna Prof. G.N. Qazi, New Delhi Prof. Talat Ahmad, New Delhi Prof. Ranjit Roy Chaudhury, New Delhi Hakim Syed Khaleefathullah, Chennai Prof. Wazahat Husain, Aligarh Dr. Nandini Kumar, New Delhi Prof. K.M.Y. Amin, Aligarh Dr. O.P. Agarawal, New Delhi Dr. A.B. Khan, Aligarh Prof. Y.K. Gupta, New Delhi Dr. Neena Khanna, New Delhi Prof. A. Ray, New Delhi Dr. Mohammad Khalid Siddiqui, Faridabad Prof. S. Shakir Jamil, New Dlehi Prof. Ghufran Ahmed, Aligarh Prof. Mansoor Ahmad Siddiqui, Bengaluru Dr. M.A. Waheed,
    [Show full text]
  • Anticancer Activity of Bicalutamide-Loaded PLGA Nanoparticles in Prostate Cancers
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 2305-2310, 2015 Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers JUN GUO1*, SHU-HONG WU2*, WEI-GUO REN3, XIN-LI WANG4 and AI-QING YANG5 1Department of Urology, The Affiliated Hospital of Taishan Medical University, Taian, Shandong 271000; 2Department of Urology, Feicheng Kuangye Central Hospital, Feicheng, Shandong 271608; 3Department of Urology, Rugao Boai Hospital, Nantong, Jiangsu 226500; 4Department of Pathology, The Affiliated Hospital of Taishan Medical University;5 Department of Pathology, The First People's Hospital of Taian, Taian, Shandong 271000, P.R. China Received October 6, 2014; Accepted August 26, 2015 DOI: 10.3892/etm.2015.2796 Abstract. Prostate cancer is the most commonly diagnosed Introduction non-cutaneous malignancy in men in western and most devel- oping countries. Bicalutamide (BLT) is an antineoplastic Men in Western countries and developing nations are hormonal agent primarily used in the treatment of locally frequently diagnosed with cancers of the prostate gland (1). advanced and metastatic prostate cancers. In the present study, Statistically, prostate cancer has overtaken heart diseases and the aim was to develop a nanotechnology-based delivery lung disorders in old people as a cause of mortality. According system to target prostate cancer cells. This involved the to estimates, >200,000 new cases of prostate cancer were development of a BLT-loaded poly(D,L-lactide-co-glycolide) reported with >30,000 mortalities during the year 2013 (2,3). PLGA (PLGA-BLT) nanoparticulate system in an attempt to A similar or higher number of cases has been projected for the improve the therapeutic efficacy of BLT in prostate cancer and year 2014 (4).
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Raloxifene for the Treatment of Triple Negative Breast Cancer
    Raloxifene for the Treatment of Triple Negative Breast Cancer Julian Dzeyk A Thesis Submitted for the Degree of Master of Science At the University of Otago, Dunedin, New Zealand Submitted on February 29th 2012 Acknowledgments I would like to sincerely thank Associate Professor Rhonda Rosengren for giving me the opportunity to work on this project as well as her help and guidance throughout the entire time. I want to greatly thank Dr Sebastien Taurin for teaching me the majority of techniques used in this study, as well as for always being there to discuss my endless questions and thoughts. I have learned a lot from you. Thank you for your continuous help. I would like to thank Babasaheb Yadav for his help and for always bringing a smile or laugh into the lab. You made the ECCO 2011 conference in Stockholm a trip to remember! Thank you. I would also like to thank Mhairi Nimick for her help around the lab, especially for tumor slicing when I had my back problems. To everyone else in the department and especially my fellow MSc students, thank you for the help and the good times. I would also like to thank my family in Germany who have always supported me in my plans and future goals and have always provided me with constructive feedback and ideas. To my dearest Steffi, thank you for your love, and your honest and continuous support. You have been a relentless source of motivation and inspiration. To Andrea and Bernard, thank you for your continuous support, your patience, your constructive criticism, your help, and most of all your love.
    [Show full text]
  • Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform
    1 Integrating a Stepped Care Model of Screening and Treatment for Depression into Malawi's National HIV Care Delivery Platform 23 February, 2021 - v1 (ID: R01MH117760) 2 Stepped Care for Depression at Integrated Chronic Care Centers (IC3D) in Malawi: Study Protocol for a Cluster Randomized Controlled Trial INTRODUCTION In low- and middle-income countries (LAMICs), mental disorders like major depression often account for a larger burden of disease than HIV and malaria combined;1 yet, three- quarters of affected individuals receive no treatment.2 The funding landscape accounts for much of this discrepancy: In 2017, international funding for HIV was $US9.5 billion, compared to $US130M for mental disorders—roughly a 70-fold difference.3 The economic impact of this under-investment, in terms of lost human capital, is expected to reach $30 trillion worldwide over a 20-year period.4 Malawi represents a paradigm case: despite being the second poorest country in the world5 and having one of the ten highest HIV incidences,6 international efforts have successfully built a system of care to address the HIV epidemic. Nevertheless, over 90% of those requiring treatment for depression have yet to receive care,7 even though depression is one of the leading causes of disability in Malawi.8 One recent study estimated the point prevalence of depression in Malawi at 19%.9 Underlying the paucity of depression care is a perception that, relative to treatments for infectious disease, treatments for mental disorders are more time-intensive and less cost- effective.10 However, research to-date has two major shortcomings: First, evaluations often study the cost of stand-alone programs, rather than leveraging existing infrastructure to integrate care, which would reduce costs.11 The HIV care platform in Malawi, comprising a network of 708 facilities, represents one such example.
    [Show full text]
  • European Journal of Pharmacology 753 (2015) 2–18
    European Journal of Pharmacology 753 (2015) 2–18 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Review Serotonin: A never-ending story Berend Olivier a,b,n a Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences & Brain Center Rudolf Magnus, Utrecht University, Universiteitsweg 99, 3584CG Utrecht, The Netherlands b Department of Psychiatry, Yale University School of Medicine, New Haven, USA article info abstract Article history: The neurotransmitter serotonin is an evolutionary ancient molecule that has remarkable modulatory Accepted 16 October 2014 effects in almost all central nervous system integrative functions, such as mood, anxiety, stress, aggression, Available online 7 November 2014 feeding, cognition and sexual behavior. After giving a short outline of the serotonergic system (anatomy, Keywords: receptors, transporter) the author's contributions over the last 40 years in the role of serotonin in Serotonin depression, aggression, anxiety, stress and sexual behavior is outlined. Each area delineates the work Depression performed on animal model development, drug discovery and development. Most of the research work Anxiety described has started from an industrial perspective, aimed at developing animals models for psychiatric Aggression diseases and leading to putative new innovative psychotropic drugs, like in the cases of the SSRI SSRI fluvoxamine, the serenic eltoprazine and the anxiolytic flesinoxan. Later this research work mainly focused Fluvoxamine on developing translational animal models for psychiatric diseases and implicating them in the search for mechanisms involved in normal and diseased brains and finding new concepts for appropriate drugs. & 2014 Elsevier B.V. All rights reserved. Contents 1. Serotonin, history, drugs .
    [Show full text]
  • Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
    Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone.
    [Show full text]
  • Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V
    Published OnlineFirst January 4, 2018; DOI: 10.1158/1078-0432.CCR-17-2168 Cancer Therapy: Preclinical Clinical Cancer Research Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V. Nimmervoll1, Nidal Boulos2, Brandon Bianski3, Jason Dapper4, Michael DeCuypere5, Anang Shelat6, Sabrina Terranova1, Hope E. Terhune4, Amar Gajjar7, Yogesh T. Patel8, Burgess B. Freeman9, Arzu Onar-Thomas10, Clinton F. Stewart11, Martine F. Roussel12, R. Kipling Guy6,13, Thomas E. Merchant3, Christopher Calabrese14, Karen D. Wright15, and Richard J. Gilbertson1 Abstract Purpose: Curing all children with brain tumors will require an Results: Mouse models displayed distinct patterns of response understanding of how each subtype responds to conventional to surgery, irradiation, and chemotherapy that varied with tumor treatments and how best to combine existing and novel therapies. subtype. Repurposing screens identified 3-hour infusions of It is extremely challenging to acquire this knowledge in the clinic gemcitabine as a relatively nontoxic and efficacious treatment of alone, especially among patients with rare tumors. Therefore, we SEP and CPC. Combination neurosurgery, fractionated irradia- developed a preclinical brain tumor platform to test combina- tion, and gemcitabine proved significantly more effective than tions of conventional and novel therapies in a manner that closely surgery and irradiation alone, curing one half of all animals with recapitulates clinic trials. aggressive forms of SEP. Experimental Design: A multidisciplinary team was established Conclusions: We report a comprehensive preclinical trial to design and conduct neurosurgical, fractionated radiotherapy platform to assess the therapeutic activity of conventional and chemotherapy studies, alone or in combination, in accurate and novel treatments among rare brain tumor subtypes.
    [Show full text]
  • Concerted but Segregated Actions of Oxytocin and Vasopressin Within the Ventral and 2 Dorsal Lateral Septum Determine Female Aggression
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.28.224873; this version posted July 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Concerted but segregated actions of oxytocin and vasopressin within the ventral and 2 dorsal lateral septum determine female aggression 3 4 Vinícius Elias de Moura Oliveira1, Michael Lukas3, Hannah Nora Wolf1, Elisa Durante1, 5 Alexandra Lorenz1, Anna-Lena Mayer1, Anna Bludau1, Oliver J. Bosch1, Valery Grinevich4, 6 Veronica Egger3, Trynke R. de Jong1,2, Inga D. Neumann1* 7 8 1Department of Neurobiology and Animal Physiology, Behavioural and Molecular 9 Neurobiology, University of Regensburg, Regensburg, Germany 10 2Medische Biobank Noord-Nederland B.V. Groningen, Netherlands 11 3Department of Neurobiology and Animal Physiology, Neurophysiology, University of 12 Regensburg, Regensburg, Germany 13 4Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, 14 Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany 15 *Corresponding author [email protected] 16 17 18 ABSTRACT: 19 In contrast to males, aggression in females has been rarely studied. Here, we established a rat 20 model of enhanced female aggression using a combination of social isolation and aggression- 21 training to specifically investigate the involvement of the oxytocin (OXT) and vasopressin 22 (AVP) systems within the lateral septum (LS). Using neuropharmacological, optogenetic, 23 chemogenetic as well as microdialyses approaches, we revealed that enhanced OXT release 24 within the ventral LS (vLS), combined with reduced AVP release within the dorsal LS (dLS), 25 are required for female aggression.
    [Show full text]
  • The 5-HT1B Receptor - a Potential Target for Antidepressant Treatment
    Psychopharmacology (2018) 235:1317–1334 https://doi.org/10.1007/s00213-018-4872-1 REVIEW The 5-HT1B receptor - a potential target for antidepressant treatment Mikael Tiger1,2 & Katarina Varnäs1 & Yoshiro Okubo2 & Johan Lundberg1 Received: 26 October 2017 /Accepted: 26 February 2018 /Published online: 15 March 2018 # The Author(s) 2018 Abstract Major depressive disorder (MDD) is the leading cause of disability worldwide. The serotonin hypothesis may be the model of MDD pathophysiology with the most support. The majority of antidepressants enhance synaptic serotonin levels quickly, while it usually takes weeks to discern MDD treatment effect. It has been hypothesized that the time lag between serotonin increase and reduction of MDD symptoms is due to downregulation of inhibitory receptors such as the serotonin 1B receptor (5-HT1BR). The research on 5-HT1BR has previously been hampered by a lack of selective ligands for the receptor. The last extensive review of 5-HT1BR in the pathophysiology of depression was published 2009, and based mainly on findings from animal studies. Since then, selective radioligands for in vivo quantification of brain 5-HT1BR binding with positron emission tomography has been developed, providing new knowledge on the role of 5-HT1BR in MDD and its treatment. The main focus of this review is the role of 5-HT1BR in relation to MDD and its treatment, although studies of 5-HT1BR in obsessive-compulsive disorder, alcohol dependence, and cocaine dependence are also reviewed. The evidence outlined range from animal models of disease, effects of 5-HT1B receptor agonists and antagonists, case-control studies of 5-HT1B receptor binding postmortem and in vivo, with positron emission tomography, to clinical studies of 5-HT1B receptor effects of established treatments for MDD.
    [Show full text]